CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy

Update: 2021-11-19

Description

This episode outlines treatment barriers associated with the use of BTK inhibitors in CLL/SLL, including adverse events. Earn CME: https://www.naccme.com/oln

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy

2021-11-1901:14:16

Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies

2021-11-1901:13:14

Metastatic HER2-Positive Breast Cancer: Newer and Emerging Treatment Considerations and Personalized Therapies

2021-11-1901:14:06

Navigating the Evolving Treatment Landscape in Prostate Cancer: A Focus on Novel Anti-androgen Therapy

2021-11-1501:12:59

Approaches for Optimal Molecular Testing, Treatment, and Management of NSCLC and Accompanying Driver Mutations

2021-11-1001:11:58

00:00

CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy

#box-pro-ellipsis-17272694559403{-webkit-line-clamp:2;}CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy

CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy

HMP Global

CLL/SLL: Managing Adverse Events Associated with BTK Inhibitor Therapy